These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33413474)

  • 41. The Role of Autophagy in Tumor Immune Infiltration in Colorectal Cancer.
    Bian-Fang Y; Dong-Ning W; Dan T; Jian-Yu S; Shi-Yi W; Ben-Jun W; Xin D; Wen-Wen Z; Qing-Feng W; Yan Z
    Anal Cell Pathol (Amst); 2022; 2022():2055676. PubMed ID: 35321516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRAS mutation and abnormal expression of Cripto-1 as two potential candidate biomarkers for detection of colorectal cancer development.
    Igder S; Mohammadiasl J; Azadpour S; Mansouri E; Ashktorab H; Mokarram P
    J Cell Biochem; 2020 Apr; 121(4):2901-2908. PubMed ID: 31692030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protocadherin γ-A7 is down-regulated in colorectal cancer and associated with the prognosis in patients with wild-type KRAS.
    Liu Y; Peng K; Xie R; Zheng J; Guo J; Wei R; Yang H; Cai C; Wei Q
    Hum Pathol; 2019 Jan; 83():14-21. PubMed ID: 30121367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
    Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
    Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value.
    Xie MZ; Li JL; Cai ZM; Li KZ; Hu BL
    BMC Gastroenterol; 2019 Mar; 19(1):46. PubMed ID: 30917791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in
    Inoue A; Mizushima T; Wu X; Okuzaki D; Kambara N; Ishikawa S; Wang J; Qian Y; Hirose H; Yokoyama Y; Ikeshima R; Hiraki M; Miyoshi N; Takahashi H; Haraguchi N; Hata T; Matsuda C; Doki Y; Mori M; Yamamoto H
    Mol Cancer Ther; 2018 May; 17(5):977-987. PubMed ID: 29545333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
    BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased expression of the RAS-GTPase activating protein RASAL1 is associated with colorectal tumor progression.
    Ohta M; Seto M; Ijichi H; Miyabayashi K; Kudo Y; Mohri D; Asaoka Y; Tada M; Tanaka Y; Ikenoue T; Kanai F; Kawabe T; Omata M
    Gastroenterology; 2009 Jan; 136(1):206-16. PubMed ID: 18992247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
    Wu K; Wu B; Yan K; Ding Q; Miao Z
    Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status.
    Schmitz KJ; Ademi C; Bertram S; Schmid KW; Baba HA
    World J Surg Oncol; 2016 Jul; 14(1):189. PubMed ID: 27444698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
    Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. miRNAs-Based Molecular Signature for
    Milanesi E; Dobre M; Bucuroiu AI; Herlea V; Manuc TE; Salvi A; De Petro G; Manuc M; Becheanu G
    J Immunol Res; 2020; 2020():4927120. PubMed ID: 32676506
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.
    Yan H; Talty R; Jain A; Cai Y; Zheng J; Shen X; Muca E; Paty PB; Bosenberg MW; Khan SA; Johnson CH
    Redox Biol; 2023 Jun; 62():102699. PubMed ID: 37086630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
    Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
    Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.